Weekly Report: what happened at PSCH last week (0429-0503)?

Organon Beats On Q1, Women's Health Leads the Charge

Organon & Co reported a 5% Y/Y increase in the first quarter of 2024 revenue. Women’s Health revenue increased by 11% as reported and 12% ex-FX. The company reported adjusted EPS of $1.22, beating the consensus.

Weekly Report: what happened at PSCH last week (0422-0426)?

Weekly Report: what happened at PSCH last week (0415-0419)?

Weekly Report: what happened at PSCH last week (0408-0412)?

Weekly Report: what happened at PSCH last week (0401-0405)?

Weekly Report: what happened at PSCH last week (0325-0329)?

PSCH: The Small-Cap Health Care Catch-Up Trade

The Invesco S&P SmallCap Health Care ETF provides access to US-based small-cap healthcare companies. Small-cap health care stocks are increasingly attractive as a catch-up trade in the sector. The fund is highly diversified, with low costs and a focus on replicating the performance of its benchmark index.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Weekly Report: what happened at PSCH last week (0318-0322)?

Taking Stock: Q2 2024 Equity Market Outlook

IHI: Technological Advances Will Continue Carrying This High-Performing Medical ETF

IShares U.S. Medical Devices ETF has demonstrated the greatest long-term performance among peer funds. Abbott Laboratories and Intuitive Surgical are key holdings of the fund. The fund is uniquely postured for growth looking forward due to its mix of top holdings. IHI has outperformed the S&P 500 Index over the past decade. The iShares fund has the highest expense ratio compared to peer healthcare and medical device funds.

Weekly Report: what happened at PSCH last week (0311-0315)?

2024 Outlook: A New 'Super Boom'? Or Chop And Churn?

PTH: Avoid This Momentum-Based Small-Cap Health Care ETF

The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) holds mostly small-cap stocks with huge recent price gains. PTH tracks the DWA Healthcare Technical Leaders Index. The fund has underperformed the Vanguard Health Care ETF by 13% over the last ten years. The flawed strategy and the speculative nature of PTH lead me to assign a "sell" rating.

Weekly Report: what happened at PSCH last week (0304-0308)?

Why Biotech Stocks May Be Ready For A Recovery

Biotech stocks have struggled in recent quarters as high interest rates take a toll on the capital-intensive sector. Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with MoneyTalk's Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a recovery.

Weekly Report: what happened at PSCH last week (0226-0301)?

Are Healthcare Stocks A Risky Prescription In A U.S. Election Year?

Weekly Report: what happened at PSCH last week (0219-0223)?